Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com
Improving Durability of Responses Is a Key Next Step for CAR T-cell Therapy in Myeloma
May 26th 2023Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.
Read More
BET Inhibition Highlights Exploration of Novel Targeted Approaches in Myelofibrosis
May 26th 2023Andrew T. Kuykendall, MD, expands on the rationale for exploring BET inhibition in the treatment of patients with myelofibrosis, details the implications of data from the MANIFEST trial, and discusses other potential targets for novel therapies for myelofibrosis.
Read More
Clinical Trials in Endometrial Cancer Need Improved Diversity to Address Rising Mortality Rates
May 25th 2023Bhavana Pothuri, MD, expands on challenges that still need to be addressed for the treatment of patients with endometrial cancer, highlights potential practice-changing data from the phase 3 NRG-GY018 and RUBY trials, details the evolving role of PARP inhibitors for patients with ovarian cancer, and touches on key emerging data from trials for patients with cervical cancer.
Read More
R. Kate Kelley, MD, details the ongoing investigation of RLY-4008 for patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, other ongoing investigations in cholangiocarcinoma, and the importance of molecular testing to drive treatment decisions in this population.
Read More
Elacestrant Highlights Promise of Oral SERDs in HR+/HER2– Metastatic Breast Cancer
May 18th 2023Antoinette R. Tan, MD, MHSc, discussed the promise of oral SERDs as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.
Read More
Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC
May 16th 2023The use of docetaxel and ramucirumab yielded antitumor activity and showcased a manageable safety profile in patients with non–small cell lung cancer who progressed on platinum-based chemotherapy and immune checkpoint inhibitors, according to data from the phase 2 SCORPION study.
Read More
OP-1250 Plus Palbociclib Demonstrates Activity, Safety in HR+/HER2– Metastatic Breast Cancer
May 14th 2023The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Hsp70 Inhibition Could Help Overcome Belzutifan Resistance in VHL Disease–Associated ccRCC
May 12th 2023Michael Basin, MD, discusses the rationale for the preclinical investigation of belzutifan resistance in ccRCC cell lines, the next steps for this research, and the potential implications for combining Hsp70 inhibition with a HIF2α inhibitor.
Read More
Nivolumab Plus Brachytherapy/ADT Improves Disease Control in Grade Group 5 Prostate Cancer
May 10th 2023John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.
Read More
Continued Development of Targeted Therapies Aims to Address Unmet Needs in CRC
May 9th 2023John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.
Read More
Interval Cytoreductive Surgery After Chemo Boosts Survival in Stage IV Epithelial Ovarian Cancer
May 8th 2023Liat Hogen, MD, FRCSC, discussed the potential benefit for cytoreductive surgery in patients with initially unresectable stage IV epithelial ovarian cancer and the implications of findings from this retrospective analysis on future clinical decisions.
Read More
Emerging Data Help Steer CDK4/6 Inhibitor Choice in HR+/HER2– Breast Cancer
May 8th 2023Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.
Read More
Pembrolizumab Could Delay Radical Cystectomy in BCG-unresponsive, High-risk NMIBC
May 7th 2023Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.
Read More
TAR-200 Monotherapy Displays Early Efficacy in BCG-Unresponsive NMIBC
May 5th 2023Sia Daneshmand, MD, discusses the rationale for investigating TAR-200 for the treatment of patients with Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer, expands on the preliminary efficacy and safety data from the SunRISe-1 trial, and more.
Read More
Gedatolisib, Fulvestrant, and Palbociclib Triplet Under Investigation in HR+/HER2– Breast Cancer
May 4th 2023The combination of gedatolisib and fulvestrant with or without palbociclib is under evaluation in the phase 3 VIKTORIA-1 trial for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor–positive/HER2-negative breast cancer who have previously progressed on first-line therapy.
Read More
Manali Bhave, MD, discusses the effect of emerging therapies on the treatment landscape for patients with HR-positive, HER2-negative or -low breast cancer, highlighted her stance on sequencing decisions for these patients, and expanded on the additional work being done to optimize treatment sequencing from a growing list of options.
Read More
VT3989 Shows Activity, Tolerability in Mesothelioma and Other NF2-Mutated Solid Tumors
April 26th 2023VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.
Read More
Furmonertinib Plus Icotinib Elicits Antitumor Activity in EGFR+ NSCLC With CNS Metastases
April 26th 2023First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.
Read More
Subgroup Analysis Shows Consistent Benefit for Dostarlimab Plus Chemo in Nonsquamous NSCLC
April 24th 2023Overall response rates were similar across subgroups of patients with nonsquamous non–small cell lung cancer for the combinations of dostarlimab-gxly plus chemotherapy and pembrolizumab plus chemotherapy, and responses numerically favored the dostarlimab-based combination in most subgroups, according to a subgroup analysis of the phase 2 PERLA trial.
Read More
Tucatinib/Trastuzumab Approval Highlights Expansion of Tailored Therapies in HER2+ CRC
April 21st 2023John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.
Read More
Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence
April 19th 2023Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.
Read More
Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.
Read More
Ganitumab Plus Interval-Compressed Chemotherapy Fails to Improve EFS in Metastatic Ewing Sarcoma
April 11th 2023R. Lor Randall, MD, FACS, expands on data from a phase 3 trial evaluating the addition of ganitumab to standard-of-care, interval-compressed chemotherapy, the implications of these results, and how the study could help inform future trials exploring other targeted therapies for the treatment of patients with metastatic Ewing sarcoma.
Read More
BXCL701 Plus Pembrolizumab Elicits Durable Responses in Small Cell Neuroendocrine mCRPC
April 10th 2023The combination of BXCL701 and pembrolizumab produced durable responses in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to data from a phase 2a trial presented at the 2023 Genitourinary Cancers Symposium.
Read More
Novel Tucatinib-based Regimens Highlight Ongoing Research in HER2+ Breast Cancer
April 10th 2023Jennifer M. Matro, MD, discusses the real-world implications and uptake of the HER2CLIMB regimen, other trials investigating tucatinib-based regimens in HER2-positive metastatic breast cancer, and how approaches differ between early-stage and metastatic hormone receptor–positive/HER2-negative breast cancer.
Read More